The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …

Importance Tests that predict outcomes for patients with acute myeloid leukemia (AML) are
imprecise, especially for those with intermediate risk AML. Objectives To determine whether …

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological
malignancy. Although immunotherapy may be an attractive modality to exploit in patients …

Abstract Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of
acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with …